{
  "id": 6623824,
  "title": "Alector at Cantor healthcare conference: brain-shuttle pipeline in focus",
  "url": "https://urgent.news/2026/09/10/alector-at-cantor-healthcare-conference-brain-shuttle-pipeline-in",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-10T18:53:18.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/alector-at-cantor-healthcare-conference-brainshuttle-pipeline-in-focus-93CH-4896723"
  },
  "original_language": "en",
  "account": "On Thursday, September 10, 2026, Alector (ALEC) addressed the 12th Annual Cantor Fitzgerald Global Healthcare Conference, emphasizing its focus on neurodegeneration. The company's brain-carrier platform and a lead Alzheimer's candidate, AL137, are at the forefront of its pipeline. Alector aims to enhance brain delivery and reduce safety problems associated with early-stage drug development. The company's shares were trading at $2.07, down 8.81% from the previous close of $2.27, with a market capitalization of $231 million. InvestingPro analysis suggests the stock is undervalued at its current level, placing Alector on the list of the platform's most undervalued stocks. Alector's proprietary brain-carrier platform is designed to move drugs across the blood-brain barrier, minimizing anemia and off-target effects. Their lead program, AL137, an anti-amyloid-beta antibody, is set to enter Phase I testing in April, starting with healthy volunteers in Australia and later in Alzheimer's patients in the U.S. Preclinical data indicates several-fold better brain exposure compared to competitor platforms, with no significant drop in red blood cells or hemoglobin in non-human primates. Alector is exploring tau, alpha-synuclein, and GCase programs and is actively seeking partnerships for Parkinson's disease assets by the end of the year.",
  "summary": null,
  "key_points": [
    "Alector focuses on neurodegeneration at Cantor conference.",
    "AL137, an anti-amyloid-beta antibody, enters Phase I testing in April.",
    "Company's brain-carrier platform shows better brain exposure in preclinical data."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}